| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 15, 2021Latest approval for PillCam™ further enables patients to receive gastrointestinal care in the comfort of their own home
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam™ Small Bowel 3...
Nov 15, 2021Four external appointments include new digital innovation leader, head of global strategy and two Operating Unit President roles within the Neuroscience Portfolio DUBLIN, Nov. 15, 2021...
Aug 24, 2021Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New Product LaunchesMedtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and...
-
Aug 6, 2021Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat...
-
May 27, 2021- Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company reported fourth quarter worldwide revenue of $8.188...
-
Feb 23, 2021
- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire/ --...
-
Feb 1, 2021
Acquisition of RIST Neurovascular Enhances Medtronic's Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions DUBLIN, Feb. 1, 2021 /PRNewswire/ -- Medtronic...
-
Nov 24, 2020
- Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic - Q2 GAAP Diluted EPS of $0.36; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN, Nov. 24, 2020 /PRNewswire/ -- Medtronic plc...
-
Nov 16, 2020
Acquisition Expands Medtronic's Artificial Intelligence and Data Capabilities, Becoming the First Company to Offer an Integrated Spine Solution Including AI-Driven Surgical Planning, Personalized...
-
Nov 12, 2020Real-Time Glucose Data Coupled with InPen's Dose Calculator Helps Users Make Better Dosing Decisions
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of InPen™ integrated with real-time1 Guardian Connect™ CGM data. InPen is the first and only...